We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-15.04%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$185M
AUM Growth
-$43.2M
Cap. Flow
+$19.8M
Cap. Flow %
10.73%
Top 10 Hldgs %
66.67%
Holding
76
New
13
Increased
20
Reduced
16
Closed
22

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$9.46M
2
ZGNX
Zogenix, Inc.
ZGNX
+$5.9M
3
RCM
R1 RCM Inc. Common Stock
RCM
+$5.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.26M
5
AMRN
Amarin Corp
AMRN
+$4.88M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.55M
2
SAGE
Sage Therapeutics
SAGE
+$4.05M
3
ABT icon
Abbott
ABT
+$3.07M
4
MDT icon
Medtronic
MDT
+$2.65M
5
ANAB icon
AnaptysBio
ANAB
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.02%
2 Industrials 10.11%
3 Miscellaneous 2.35%
4 Real Estate 0.52%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
$1.41M 0.76%
106,880
+6,585
+7% +$101K
LOXO
27
DELISTED
Loxo Oncology, Inc
LOXO
$1.4M 0.76%
+10,000
New +$1.52M
BSTC
28
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.33M 0.72%
22,000
+100
+0.5% +$5.97K
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.51B
$1.32M 0.72%
163,959
+15,000
+10% +$117K
XENE icon
30
Xenon Pharmaceuticals
XENE
$5.81B
$1.29M 0.7%
205,104
-4,635
-2% -$41.2K
ARRY
31
DELISTED
Array Biopharma Inc
ARRY
$1.29M 0.7%
90,412
+30,000
+50% +$455K
FOMX
32
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.06M 0.57%
294,660
+20,843
+8% +$90.6K
AFMD
33
DELISTED
Affimed
AFMD
$1.04M 0.57%
33,577
-9,696
-22% -$361K
CTRE icon
34
CareTrust REIT
CTRE
$9.22B
$956K 0.52%
51,264
– –
ASND icon
35
Ascendis Pharma A/S
ASND
$16.3B
$956K 0.52%
15,254
-3,800
-20% -$239K
TCDA
36
DELISTED
Tricida, Inc. Common Stock
TCDA
$956K 0.52%
40,522
+16,400
+68% +$471K
ARQL
37
DELISTED
Arqule Inc
ARQL
$955K 0.52%
344,618
+55,000
+19% +$210K
PBYI icon
38
Puma Biotechnology
PBYI
$468M
$861K 0.47%
42,301
+20,630
+95% +$619K
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$792K 0.43%
8,271
-35,350
-81% -$4.05M
ELV icon
40
Elevance Health
ELV
$85.5B
$604K 0.33%
2,300
– –
FOLD
41
DELISTED
Amicus Therapeutics
FOLD
$601K 0.33%
62,750
-17,000
-21% -$187K
NTRA icon
42
Natera
NTRA
$47B
$552K 0.3%
+39,539
New +$722K
CNC icon
43
Centene
CNC
$32B
$496K 0.27%
8,600
– –
ALBO
44
DELISTED
Albireo Pharma Inc
ALBO
$442K 0.24%
18,029
– –
DRNA
45
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$439K 0.24%
41,074
-10,000
-20% -$132K
LAB icon
46
Standard BioTools
LAB
$252M
$435K 0.24%
+50,455
New +$393K
CBAY
47
DELISTED
Cymabay Therapeutics
CBAY
$371K 0.2%
47,096
-25,000
-35% -$238K
IVC
48
DELISTED
Invacare Corporation
IVC
$318K 0.17%
73,902
-35,000
-32% -$309K
SPNE
49
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$282K 0.15%
15,459
-15,440
-50% -$261K
TGTX icon
50
TG Therapeutics
TGTX
$8.26B
$267K 0.14%
65,000
– –
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Eversept Partners held 76 positions worth $185M, down 19% from $228M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Eversept Partners deployed $19.8M of net new capital in Q4 2018, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Fate Therapeutics: 165,000 shares worth $2.12M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 79% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Merck, an estimated $7.55M trimmed.

  • Eversept Partners's largest Q4 2018 buy was Fate Therapeutics: 165,000 shares worth $2.12M.
  • Eversept Partners added most to GSK in Q4 2018, an estimated $9.46M increase.
  • Eversept Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $7.55M.
  • Eversept Partners fully exited Medtronic in Q4 2018, selling an estimated $2.65M.
  • Eversept Partners's ten largest holdings make up 67% of its $185M portfolio in Q4 2018.
  • Eversept Partners opened 13 new positions and closed 22 in Q4 2018.
  • Eversept Partners's portfolio value fell 19% quarter-over-quarter to $185M.

Based on Eversept Partners's 13F filing for Q4 2018, filed 13 Feb 2019.